DSM N.V.
EURONEXT AMSTERDAM : DSM

June 06, 2012 02:25 ET

DSM announces expiration of waiting period under Hart-Scott-Rodino Act

HEERLEN, NETHERLANDS--(Marketwire - Jun 6, 2012) - Royal DSM (EURONEXT AMSTERDAM: DSM), the global Life Sciences and Materials Sciences company, announced today the expiration of the mandatory waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, for its previously announced tender offer for all outstanding shares of common stock of Kensey Nash Corporation (NASDAQ: KNSY) at a price of $38.50 per share (the "Offer"). This condition of the Offer is thus satisfied.

The Offer remains subject to the satisfaction of certain other conditions. The Offer is scheduled to expire at 12:00 midnight (New York City time) at the end of Monday, June 18, 2012, unless the Offer is extended.

Kensey Nash

Kensey Nash is a medical device company primarily focused on regenerative medicine utilizing its proprietary collagen and synthetic polymer technology. The company is recognized as a leader for innovative product development and unique technology in the field of resorbable biomaterials. The company has an extensive range of products, which are sold through strategic partners in multiple medical markets, including the cardiology, orthopedic, sports medicine, spine, trauma, craniomaxillofacial and general surgery markets. For more information, visit http://www.kenseynash.com.

DSM - Bright Science. Brighter Living.™

Royal DSM is a global science-based company active in health, nutrition and materials. By connecting its unique competences in Life Sciences and Materials Sciences DSM is driving economic prosperity, environmental progress and social advances to create sustainable value for all stakeholders. DSM delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, pharmaceuticals, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials. DSM's 22,000 employees deliver annual net sales of around EUR9 billion. The company is listed on NYSE Euronext. More information can be found at www.dsm.com.


Press release-pdf: http://hugin.info/130663/R/1617576/516198.pdf


This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: DSM N.V. via Thomson Reuters ONE

[HUG#1617576]

Contact Information

  • For more information:

    DSM Corporate Communications
    Herman Betten
    tel. +31 (0) 45 5782017
    fax +31 (0) 45 5740680
    e-mail Email Contact

    DSM Investor Relations
    Hans Vossen
    tel. +31 (0) 45 5782864
    fax +31 (0) 10 4590275
    e-mail Email Contact

    Kensey Nash
    Joseph W. Kaufmann
    Tel. +1 484 713 2100